Company Performance - Flux Power Holdings, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, but an improvement from a loss of $0.16 per share a year ago, indicating a surprise of -33.33% [1] - The company posted revenues of $16.74 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.62% and showing an increase from $14.46 million in the same quarter last year [2] - Over the last four quarters, Flux Power has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates twice [2] Stock Performance - Flux Power shares have increased by approximately 20.9% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $16.61 million, and for the current fiscal year, it is -$0.36 on revenues of $65.9 million [7] Industry Outlook - The Electronics - Miscellaneous Products industry, to which Flux Power belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Flux Power's stock performance [5]

Company Performance - BioLife Solutions, Inc. reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 233.33% [1] - The company achieved revenues of $23.94 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.28%, although this represents a decline from year-ago revenues of $31.73 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS estimates [2] Stock Performance - BioLife Solutions shares have declined approximately 17.8% since the beginning of the year, in contrast to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $23.29 million, and for the current fiscal year, it is -$0.09 on revenues of $97.18 million [7] Industry Outlook - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of BioLife Solutions may be influenced by the overall outlook of the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Group 1 - Expedia reported quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.42 per share, but showing an increase from $0.21 per share a year ago, resulting in an earnings surprise of -4.76% [1] - The company posted revenues of $2.99 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.27%, compared to $2.89 billion in the same quarter last year [2] - Over the last four quarters, Expedia has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed, losing about 10.6% since the beginning of the year, while the S&P 500 declined by -4.3% [3] - The current consensus EPS estimate for the coming quarter is $4.05 on revenues of $3.74 billion, and for the current fiscal year, it is $14.31 on revenues of $14.33 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the industry [8]

Core Viewpoint - Collegium Pharmaceutical reported quarterly earnings of $1.49 per share, exceeding the Zacks Consensus Estimate of $1.43 per share, and showing a slight increase from $1.45 per share a year ago, indicating a 4.20% earnings surprise [1][2] Financial Performance - The company achieved revenues of $177.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.08%, and up from $144.92 million in the same quarter last year [2] - Over the last four quarters, Collegium Pharmaceutical has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Collegium Pharmaceutical shares have declined approximately 5.6% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.61, with projected revenues of $181.28 million, and for the current fiscal year, the EPS estimate is $6.88 on revenues of $741.38 million [7] - The outlook for the Medical - Drugs industry, where Collegium operates, is favorable, ranking in the top 26% of over 250 Zacks industries, suggesting potential for outperformance [8]

Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.86 per share when it actually produced earnings of $0.91, delivering a surprise of 5.81%.Over the last four quarters, the company ...

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...

Nerdy Inc. (NRDY) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.71%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%.Over the last four quarters, the company has surpassed con ...

Company Performance - Texas Roadhouse reported quarterly earnings of $1.70 per share, missing the Zacks Consensus Estimate of $1.75 per share, representing an earnings surprise of -2.86% [1] - The company posted revenues of $1.45 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.53%, compared to year-ago revenues of $1.32 billion [2] - Over the last four quarters, Texas Roadhouse has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - Texas Roadhouse shares have lost about 5.1% since the beginning of the year, while the S&P 500 has declined by -4.3% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $1.95 for the coming quarter and $6.93 for the current fiscal year [4][7] - The current Zacks Rank for Texas Roadhouse is 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Retail - Restaurants industry, to which Texas Roadhouse belongs, is currently in the bottom 22% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can materially affect stock performance [5][8]

Financial Performance - Celldex Therapeutics reported a quarterly loss of $0.81 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.75, and compared to a loss of $0.56 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.7 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 62.29%, while revenues a year ago were $0.16 million [2] - Over the last four quarters, Celldex has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Celldex shares have declined approximately 25.2% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current Zacks Rank for Celldex is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.81 on revenues of $1.84 million, and for the current fiscal year, it is -$3.38 on revenues of $7.33 million [7] - The estimate revisions trend for Celldex is mixed, and future earnings expectations will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Celldex belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Celldex's stock performance [5]

Core Viewpoint - RPM International's shares have increased by approximately 3.5% over the past month, outperforming the S&P 500, but there are concerns about a potential pullback as estimates have trended downward leading up to the next earnings release [1]. Group 1: Earnings Report and Market Reaction - The most recent earnings report indicated a positive trend in share performance, but the consensus estimate has shifted downward by 9.66% in the past month [2]. - Investors and analysts are closely monitoring the stock's performance as the next earnings release approaches [1]. Group 2: VGM Scores and Investment Strategy - RPM International has an average Growth Score of C, a Momentum Score of F, and a Value Score of D, placing it in the bottom 40% for the value investment strategy [3]. - The overall aggregate VGM Score for the stock is D, suggesting a lack of strong performance across multiple investment strategies [3]. Group 3: Outlook and Future Expectations - The downward trend in estimates indicates a negative outlook for RPM International, reflected in its Zacks Rank of 4 (Sell) [4]. - The expectation is for below-average returns from the stock in the upcoming months [4].